Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00803049 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
742
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi